

Zoumpourlis Vassilis

Director of Research, Head of the research team of Biomedical Applications Unit and is also head of the certified NHRF animal facility Institute of Chemical Biology

Phone: +30-210-7273730 (Office), 7273731 (Lab)

Fax: +30 210 7273677

E-mail: vzub@eie.gr

Website: <http://www.eie.gr/nhrf/institutes/ibrb/serviceunits/bau-en.html>

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
Univ. J E Purkyne, Brno, Czech Rep. (1981-1986)	Diploma	5	Mol. Biology and
Univ. J E Purkyne, Brno, Czech Rep. (1986-1987)	M.Sc.	1	Mol. Genetics
Nat Hellenic Research Foundation (1989-1994)	PhD	4	Mol. Biology of HIV-1
Nat Hellenic Research Foundation (1994-1998)	Post-Doc	5	Mol. Biology of cancer

Positions and Employment

1989-1994 PhD, IBRB, NHRF Post-Doc

1994-1998 Post-Doc

1998-2003 Functional Scientist, Grade B, IBMCB, NHRF

2003-2006 Functional Scientist, Grade A, IBMCB, NHRF

2006-2013 Research Associate Professor, IBMCB, NHRF

2013- Research Professor, Researcher A, IBMCB, NHRF

2002- Head of the research team of Biomedical Applications Unit, IBMCB, NHRF

RESEARCH ACTIVITIES ABROAD

1992	Visitor researcher, Molecular Oncology Group, Department of Clinical Dental Sciences, The University of Liverpool, UK
1993	Visitor researcher, Molecular Oncology Group, Department of Clinical Dental Sciences, The University of Liverpool, UK
1995	Visitor researcher, Marie Curie Institute, Paris, France
1998	Visitor researcher, Department of Molecular Cell Biology, Sylvius Laboratory, Leiden, Netherlands
2002	Visitor researcher, Department of Molecular Biology, Amsterdam, Netherlands

2004	Visitor researcher, Department of Molecular Oncology, Mazaryk Institute, Brno, Czech R
2005	Visitor researcher, Department of Molecular Oncology, Mazaryk Institute, Brno, Czech R
2007	Visitor researcher, Paterson Institute, Department of Cancer Research, Manchester, UK
2007	Visitor researcher, Roy Castle Lung Cancer Institute, The University of Liverpool, Department of Clinical and Molecular Cancer Medicine, UK
2008	Visitor researcher, UCSF Comprehensive Cancer Center, University of California, San Francisco, USA

i. Research Records

- ***Publications in International peer review Scientific Journals: 109***
- ***Book monography: 1***
- ***Full publications list:***
<http://www.ncbi.nlm.nih.gov/pubmed?term=zoumpourlis%20v>
- ***Total Impact Factor: IF > 600***
- ***Average Value of Impact Factor per publication: 5,5***
- ***Citations: 6298 (2/ 12/ 2021, My google scholar citation)***
- ***h-Index = 37 (5/ 6/ 2022, My google scholar citation)***
- ***Publications in Proceedings of Greek and International conferences: 39***
- ***Publications in Greek: 25***

ii. Experience in Education

Supervision of 10 diplomas, 13 Master thesis, 17 PhD thesis and 8 Post-Doc Researchers. 2004-2022: Lecturer at Msc classes, Medical School, University of Athens Pharmaceutical Department, University of Patras, Molecular Biology Department, Democretian, University of Thrace, Faculty of Biology, Kapodistrian University of Athens, University of Ioannina faculty of Biotechnology, Medical School of Creta. Topic: Molecular mechanisms of cancer in mouse and human models, stem cell biology.

iii. Research Interests

The interests of Dr Vasilis Zoumpourlis' group cover the field of the molecular biology of cancer, mainly the study of genes with a crucial role in the molecular mechanisms of multistage carcinogenesis and metastasis. More specifically our research interests include the identification of reliable biomarkers with prognostic and predictive significance for patients with prostate cancer and patients with head and neck cancer; the upper aim is to significantly contribute towards a more accurate diagnosis, better risk stratification and the identification of patient personalized response to treatments. Dr Vasilis Zoumpourlis' group has recently extended its activities towards the intriguing research of stem cells and their applications in cancer therapeutics. The current challenge of the group is to develop new

generation translational products for cytotherapy-based cancer management and testing of drugs. To this end, the group recently transferred its long-term experience and know-how in molecular biology of cancer in the emerging field of stem-cell biology, in order (a) to design stem cell-based vehicles for effective and specific tumor targeting and (b) to develop improved in vitro preclinical assays for quick and reliable assessing of toxicology and safety profiles of drugs.

iv. Honors and Awards

1981: Scholarship from Univ. J E Purkyne, Brno, Czech Republic (best performance)
1982: Scholarship from Univ, J E Purkyne, Brno, Czech Republic (best performance)
1983: Scholarship from Univ. J E Purkyne, Brno, Czech Republic (best performance)
1984: Scholarship from Univ. J E Purkyne, Brno, Czech Republic (best performance)
1985: Scholarship from Univ. J E Purkyne, Brno, Czech Republic (best performance)
1996: Hellenic Pneumonological Society, March 1996, 3rd prize
2000: Hellenic Society of General Pathology and Pathological Anatomy, 1st Galinos prize
2000: University of Athens, January, 3rd prize
2002: 4th Hellenic Conference of Cancer markers, 3rd prize
2007: 2nd Bioscience Conference, University of Patras, 1st prize
2007: 2nd Bioscience Conference, University of Patras, 2nd prize
2007: Fullbright award for academic period 2007-2008, for research in UCSF Comprehensive Cancer Center, University of California, San Francisco
2009 : 3rd International Kallikrein Symposium, Minch Germany, 1st prize.

v. Reviewer for scientific journals

BBA–Molecular Cell Research, BMC Cancer, Plos One, Carcinogenesis, Molecular Carcinogenesis, Oncogene, Cancer Letters, Cancer Biomarkers, Clinical Biochemistry, International Journal of Cancer, Tumor Biology, Advances Biomedicina, Oncotarget.

vi. Reviewer for grants

Ministry of Education, Greek Secretariat of Research and Technology, IPE Cyprus, The Czech Ministry of Education, The Austrian Federal Ministry of Education, The Italian Ministry of Education, The Poland Ministry of Education, The South Arabia Ministry of Education.

vii. Invited speaker: >60

viii. Funding: > 3500 KEuros

viii. Group Structure and Personnel

Members of the team from 2018 to present

Vassilis Zoumpourlis PhD, Research Director

Manthos Papadopoulos Research Emeritus

Post-docs

Maria Adamaki (1/11/2018-): Cancer Biomarkers

Ioannis Christodoulou (2012-): Stem cell Biology

PhDs

Nikos Houri (2016-2020): kallikrein 6 (KLK-6) in inflammation and cancer of skin.

Maria Goulielmaki (2018-2021): Toxicity, stem cell-based cancer cytotherapy, nanomedicine.

Stella Baliou (2018-2021): Taurin derivatives and anticancer therapy.

Collaborative PhDs

Hellen Zingou. (2016-2019), PhD Thesis: «Generation and characterization of novel mouse models to validate the role of KLK5 protease in inflammation for pharmacological applications» University of Patras, Department of Pharmacy, Biomedical Applications Unit, Institute of Chemical Biology, NHRF

Christina Karavassili. (2017-2020), PhD Thesis. «Development of innovative peptide vectors with self-assembly properties for local administrations». Department of Molecular Biology & Genetics (MBG) of Democritus University of Thrace, Biomedical Applications Unit, Institute of Chemical Biology, NHRF

Pelagia Chodrou. (2017-2021). PhD Thesis. «The mechanisms of effects of probiotic organisms in vitro and in vivo systems.». Department of Molecular Biology & Genetics (MBG) of Democritus University of Thrace, Biomedical Applications Unit, Institute of Chemical Biology, NHRF

Masters

Eirini Moisidou. Master Thesis. The inducible immunopuripotent stem cells: Cytotherapy in regenerative medicine and in human disease design. Biomedical Applications Unit, Institute of Chemical Biology, NHRF and Medical School of Athens, Department of Physiology (2017-2018)

George Drillis. Master Thesis. LnRNAs: Regulation, function and cancer. Biomedical Applications Unit, Institute of Chemical Biology, NHRF and Medical school of Crete (2019-2020)

Aria Simatou. Master Thesis. Historical retrospective of the SRC oncogene and new perspectives. Biomedical Applications Unit, Institute of Chemical Biology, NHRF and Medical school of Crete (2019-2020)

Kaliopi Iordanidou. Master Thesis. Historical retrospective analysis of the p53 gene.

Biomedical Applications Unit, Institute of Chemical Biology, NHRF and Medical school of Crete (2020-2021)

Alexadros Karagianakos. Master Thesis. " Targeting oncogenic pathways in the era of Personalized Oncology: A systemic analysis reveals highly mutated signalling pathways on cancer patients and puts therapeutic targets on display. Biomedical Applications Unit, Institute of Chemical Biology, NHRF and Medical school of Crete (2021-2022)

Maria Francesca. Master Thesis. "The evolution of the p53 molecules and the p53-MDM2 interaction". Biomedical Applications Unit, Institute of Chemical Biology, NHRF and Medical school of Crete (2021-2022)

Katerina Vourlia. Master Thesis. "STUDY OF THE TRANSCRIPTIONAL REPRESSOR ERF IN PROSTATE CANCER". Medical school of Crete Biomedical Applications Unit, Institute of Chemical Biology, NHRF. (2021-2022)

Undergraduate Students, Internships

Maria Margariti. Diploma. The Wharthon jelly stem cells as a tool for cancer cytotherapy. University of Ioannina, Department of of Biological Applications and Technology and Biomedical Applications Unit, Institute of Chemical Biology, NHRF 2017-2018.

Hellen Zervopoulou. Diploma: «In vitro and in vivo studies of the anticancer properties of natural products in cancer cell models». Biomedical Applications Unit, Institute of Chemical Biology, NHRF and University of Athens, Department of Biology 2018 -2019

Practical exercise of undergraduate students

Kefalas F. "In vitro study of cytotoxicity of selected nanoparticles in standard cell systems." 2021, 2-month internship. University of Athens Department of Biology

Theodoropoulou M. "In vitro study of cytotoxicity of newly synthesized chemicals and putative drugs in standard cell systems." 2021, 2-month internship. University of Ioannina, Department of of Biological Applications

Kokkinogenis L. " In vitro study of cytotoxicity of selected nanoparticles in standard cell systems." 2020, 2-month internship. University of Ioannina, Department of of Biological Applications

Papakostopoulou S. "In vitro study of cytotoxicity of newly synthesized chemicals and putative drugs in standard cell systems." 2020, 2-month internship. University of Thessali, Department of Biotechnology

Kotsari M. " In vitro study of cytotoxicity of chemicals in cancerous and non-malignant cells." 2020, 2-month internship

Dalli E. " In vitro study of cytotoxicity of nanomaterials and drugs in standard cell systems." 2019, 2-month internship

Zoumpourlis P. " In vitro study of cytotoxicity of nanomaterials and drugs in standard cell systems. " 2020, 2-month internship. University of Ioannina, Department of of Biological Applications and Technology

Georgia Taktikou (1/7/2018-30/8/2018)- University of Athens Department of Biology.

Despina Voulgari (1/7/2022-30/8/2022.) - University of Ioannina, Department of of Biological Applications

Zoumpourlis P. (1/7/2022-30/8/2022.). University of Ioannina, Department of of Biological Applications and Technology

Collaborations

Institute of Chemical Biology, National Hellenic Research Foundation

Dr Maria Zervou

Dr Ioannis Kostas

Dr Dimitris Papahatjis

Dr Vasilis Souliotis

Dr Olga Papadodima

Dr Theodora Kalogeropoulou

Dr Christos Chochos

Institute of Theoretical and Physical Chemistry, National Hellenic Research Foundation

Dr Nikos Tagmatarchis

National

Prof. G Sotiropoulou: Department of Pharmacy, University of Patras

Assoc Prof G Pampalakis: Department of Pharmacy, University of Thessaloniki

Dr Kostas Baxevanis: Cancer Immunology & Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece

Prof Ioannis Trougakos: Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 15784, Athens, Greece

Prof. Manolis Rizos: Second Department of Psychiatry, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens 12462, Greece.

Prof Dimitrios Spandidos: Laboratory of Clinical Virology, School of Medicine, University of Crete, Heraklion 71003, Greece

Prof Dimitrios Fatouros: Department of Pharmacy, University of Thessaloniki

Prof Kostas Avgoustakis: Department of Pharmacy, University of Patras

International

Dr Agelliki Malliri, Cancer Research UK Paterson Institute for Cancer Research, University of Manchester, UK

Prof Allan Balmain, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA

Dr Borek Vojtesek: Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 65653, Czech Republic

Dr Tanya Kadiyska: Department of Physiology and Pathophysiology, Medical University, 1413 Sofia, Bulgaria

Dr Robin Fahraeus: Institut de Génétique Moléculaire, INSERM Unité 940, Université Paris VII, Hôpital St Louis, Paris, France

Prof. M Hirstka: Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 65653, Czech Republic

Prof Michalis Panagiotidis: Department of Applied Sciences, Northumbria University, Newcastle Upon Tyne NE1 8ST, UK. m.panagiotidis@northumbria.ac.uk.

List of publications

Peer-reviewed Publications

1. Efsthathiou V, Stefanou MI, Demetriou M, Siafakas N, Makris M, Tsvigoulis G, Zoumpourlis V, Kypourouopoulos SP, Tsoporis JN, Spandidos DA, Smyrnis N, Rizos E. Long COVID and neuropsychiatric manifestations (Review). **Exp Ther Med.** **2022 May;23(5):363.** doi: 10.3892/etm.2022.11290. Epub 2022
2. Kadiyska T, Tourtourikov I, Dabchev K, Madzharova D, Tincheva S, Spandidos DA, Zoumpourlis V. Role of testis-specific serine kinase 1B in undiagnosed male infertility. **Mol Med Rep.** **2022 Jun;25(6):204.** doi: 10.3892/mmr.2022.12720. Epub 2022 Apr 29. PMID: 35485285.
3. Goulielmaki M, Davanos N, Kogionou P, Batsaki P, Stokidis S, Adamaki M, Mosa E, Vasilakou E, Zambatis C, Gritzapis AD, Zoumpourlis V, Baxevanis CN, Fortis SP The impact of radiation therapy on the TCR V β chain repertoire in patients with prostate cancer. **Int J Oncol.** **2022 Jun;60(6):71.** doi: 10.3892/ijo.2022.5361. Epub 2022 Apr 21. PMID: 35445738 Free PMC article.
4. Karagiannakos A, Adamaki M, Tsintarakis A, Vojtesek B, Fahraeus R, Zoumpourlis V, Karakostis K. Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. **Cancers (Basel).** **2022 Jan 28;14(3):664.** doi: 10.3390/cancers14030664. PMID: 35158934 Free PMC article. Review.
5. Christodoulou I, Goulielmaki M, Kritikos A, Zoumpourlis P, Koliakos G, Zoumpourlis V. Suitability of Human Mesenchymal Stem Cells Derived from Fetal Umbilical Cord (Wharton's Jelly) as an Alternative In Vitro Model for Acute Drug Toxicity Screening.

- Cells.** 2022 Mar 24;**11(7):1102**. doi: 10.3390/cells11071102. PMID: 35406666
Free PMC article.
6. Efsthathiou V, Stefanou MI, Siafakas N, Makris M, Tsvigoulis G, Zoumpourlis V, Spandidos DA, Smyrnis N, Rizos E. Suicidality and COVID-19: Suicidal ideation, suicidal behaviors and completed suicides amidst the COVID-19 pandemic (Review). **Exp Ther Med.** 2022 Jan;**23(1):107**. doi: 10.3892/etm.2021.11030. Epub 2021 Dec 2. PMID: 34976149 Free PMC article. Review.
 7. Constantin N, Baxevas 1, Angelos D, Gritzapis , Ioannis F, Voutsas , Panagiota Batsaki , Maria Goulielmaki , Maria Adamaki , Vassilios Zoumpourlis and Sotirios P. Fortis. T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker. **Cancers** 2022, **14**, 2674. <https://doi.org/10.3390/cancers14112674>
 8. Baliou S, Goulielmaki M, Ioannou P, Cheimonidi C, Trougakos IP, Nagl M, Kyriakopoulos AM, Zoumpourlis V. (2021). Bromamine T (BAT) Exerts Stronger Anti-Cancer Properties than Taurine (Tau). **Cancers (Basel).** **13(2):182**. doi: 10.3390/cancers13020182. **I**
 9. Giannopoulou I, Galinaki S, Kollintza E, Adamaki M, Kympouropoulos S, E, Tsamakias K, Tsangaris I, Spandidos DA, Siafakas N, **Zoumpourlis V**, Rizos E. (2021). COVID-19 and post-traumatic stress disorder: The perfect 'storm' for mental health (Review). **Exp Ther Med.** **22(4):1162**. doi: 10.3892/etm.2021.10596
 10. Pampalakis G, Zingkou E, Zoumpourlis V, Sotiropoulou G. (2021). Ectopic expression of KLK6 in MDA-MB-435 melanoma cells reduces tumorigenicity in vivo. **Pathol Res Pract.** **217:153276**. doi: 10.1016/j.prp.2020.153276.
 11. Mitsiogianni M, Trafalis DT, Franco R, Zoumpourlis V, Pappa A, Panayiotidis MI. (2021). Sulforaphane and iberin are potent epigenetic modulators of histone acetylation and methylation in malignant melanoma. **Eur J Nutr.** **60(1):147-158**. doi: 10.1007/s00394-020-02227-y.
 12. Adamaki M, Zoumpourlis V. (2021) Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer. **Cancers (Basel).** **6;13(2):173**. doi: 10.3390/cancers13020173
 13. Baliou S, Adamaki M, Ioannou P, Pappa A, Panayiotidis MI, Spandidos DA, Christodoulou I, Kyriakopoulos AM, Zoumpourlis V. (2021). Protective role of taurine against oxidative stress (Review). **Mol Med Rep.** **24(2):605**. doi: 10.3892/mmr.2021.12242.
 14. Adamaki M, Zoumpourlis V. (2021). Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. **Pharmacol Ther.** **24;228:107932**. doi: 10.1016/j.pharmthera.2021.107932
 15. Drillis G, Goulielmaki M, Spandidos DA, Aggelaki S, Zoumpourlis V. (2021). Non-coding RNAs (miRNAs and lncRNAs) and their roles in lymphogenesis in all types of lymphomas and lymphoid malignancies. **Oncol Lett.** **21(5):393**. doi: 10.3892/ol.2021.12654.
 16. Baliou S, Sofopoulos M, Goulielmaki M, Spandidos DA, Ioannou P, Kyriakopoulos AM, Zoumpourlis V. (2021). Bromamine T, a stable active bromine compound, prevents the LPS-induced inflammatory response. **Int J Mol Med.** **47(4):37**. doi: 10.3892/ijmm.2021.4870.
 17. Kokkinelis E, Deli M, Papakostopoulou S, Kotsari M, Zoumpourlis P, Goulielmaki M and **V Zoumpourlis**. (2021) Review of the applications of mouse models in cancer research **ARCHIVES OF HELLENIC MEDICINE** **38(2):166-176**
 18. Kotsari M, Kokkinelis E, Deli M, Papakostopoulou S, Zoumpourlis P, Goulielmaki M and **V Zoumpourlis**. (2021) Review of the applications of iPSCs and their role in cancer. **ARCHIVES OF HELLENIC MEDICINE** **38(4):459-470**
 19. Zoumpourlis V, Goulielmaki M, Rizos E, Baliou S, Spandidos DA. [Comment] The COVID-19 pandemic as a scientific and social challenge in the 21st century. **Mol Med**

- Rep. 2020 Jul 30.** doi: 10.3892/mmr.2020.11393. Online ahead of print. PMID: 32945405
20. Simatou A, Simatos G, Goulielmaki M, Spandidos DA, Baliou S, Zoumpourlis V. Historical retrospective of the SRC oncogene and new perspectives (Review). *Mol Clin Oncol.* **2020 Oct;13(4):21.** doi: 10.3892/mco.2020.2091. Epub 2020 Jul 14. PMID: 32765869
 21. Baliou S, Kyriakopoulos AM, Spandidos DA, Zoumpourlis V. Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review). *Int J Oncol.* **2020 Sep;57(3):631-664.** doi: 10.3892/ijo.2020.5100. Epub 2020 Jul 14. PMID: 32705269
 22. Baliou S, Kyriakopoulos AM, Goulielmaki M, Panayiotidis MI, Spandidos DA, Zoumpourlis V. Significance of taurine transporter (TauT) in homeostasis and its layers of regulation (Review). *Mol Med Rep.* **2020 Sep;22(3):2163-2173.** doi: 10.3892/mmr.2020.11321. Epub 2020 Jul 9. PMID: 32705197
 23. Sommerova L, Ondrouskova E, Martisova A, Zoumpourlis V, Galtsidis S, Hrstka R ZEB1/miR-200c/AGR2: A New Regulatory Loop Modulating the Epithelial-Mesenchymal Transition in Lung Adenocarcinomas. *Cancers (Basel).* **2020 Jun 18;12(6):1614.** doi: 10.3390/cancers12061614. PMID: 32570918
 24. Mitsiogianni M, Trafalis DT, Franco R, Zoumpourlis V, Pappa A, Panayiotidis MI. Sulforaphane and iberin are potent epigenetic modulators of histone acetylation and methylation in malignant melanoma. *Eur J Nutr.* **2020 Mar 25.** doi: 10.1007/s00394-020-02227-y. Online ahead of print. PMID: 32215717
 25. Kyriakopoulos AM, Nagl M, Orth-Höller D, Marcinkiewicz J, Baliou S, Zoumbourlis V. Successful treatment of a unique chronic multi-bacterial scalp infection with N-chlorotaurine, N-bromotaurine and bromamine T. *Access Microbiol.* **2020 Apr 24;2(7):acmi000126.** doi: 10.1099/acmi.0.000126. eCollection 2020. PMID: 32974590
 26. Goulielmaki M, Assimomytis N, Rozanc J, Taki E, Christodoulou I, Alexopoulos LG, Zoumpourlis V, Pintzas A, Papahatjis D DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties. *Transl Oncol.* **2019 Jul;12(7):932-950.** doi: 10.1016/j.tranon.2019.04.005. Epub 2019 May 13, PMID: 31096110
 27. Karavasili C, Andreadis DA, Katsamenis OL, Panteris E, Anastasiadou P, Kakazanis Z, Zoumpourlis V, Markopoulou CK, Koutsopoulos S, Vizirianakis IS, Fatouros DG Synergistic Antitumor Potency of a Self-Assembling Peptide Hydrogel for the Local Co-delivery of Doxorubicin and Curcumin in the Treatment of Head and Neck Cancer. *Mol Pharm.* **2019 Jun 3;16(6):2326-2341.** doi: 10.1021/acs.molpharmaceut.8b01221. Epub 2019 May 8. PMID: 31026168
 28. Mitsiogianni M, Koutsidis G, Mavroudis N, Trafalis DT, Botaitis S, Franco R, Zoumpourlis V, Amery T, Galanis A, Pappa A, Panayiotidis MI. The Role of Isothiocyanates as Cancer Chemo-Preventive, Chemo-Therapeutic and Anti-Melanoma Agents. *Antioxidants (Basel).* **2019 Apr 18;8(4):106.** doi: 10.3390/antiox8040106. PMID: 31003534
 29. Pampalakis G, Zingkou E, Sidiropoulos KG, Diamandis EP, Zoumpourlis V, Yousef GM, Sotiropoulou G. Biochemical pathways mediated by KLK6 protease in breast cancer. *Mol Oncol.* **2019 Nov;13(11):2329-2343.** doi: 10.1002/1878-0261.12493. Epub 2019 Sep 30. PMID: 30980596
 30. STELLA BALIOU, MARIA ADAMAKI, DEMETRIOS A. SPANDIDOS, ANTHONY M. KYRIAKOPOULOS, IOANNIS CHRISTODOULOU and VASSILIS ZOUMPOURLIS. The microbiome, its molecular mechanisms and its potential as atherapeutic strategy against colorectal carcinogenesis (Review). *WORLD ACADEMY OF SCIENCES JOURNAL 1: 3-19, 2019.* DOI: 10.3892/wasj.2018.6

31. Mitsiogianni M, Mantso T, Trafalis DT, Vasantha Rupasinghe HP, Zoumpourlis V, Franco R, Botaitis S, Pappa A, Panayiotidis MI. Allyl isothiocyanate regulates lysine acetylation and methylation marks in an experimental model of malignant melanoma. *Eur J Nutr.* **2020 Mar;59(2):557-569.** doi: 10.1007/s00394-019-01925-6. Epub 2019 Feb 14. PMID: 30762097
32. Christodoulou I, Goulielmaki M, Devetzi M, Panagiotidis M, Koliakos G, Zoumpourlis V. Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review. *Stem Cell Res Ther.* **2018 Dec 7;9(1):336.** doi: 10.1186/s13287-018-1078-8. PMID: 30526687
33. Angelopoulou A, Kolokithas-Ntoukas A, Papaioannou L, Kakazanis Z, Khoury N, Zoumpourlis V, Papatheodorou S, Kardamakis D, Bakandritsos A, Hatziantoniou S, Avgoustakis K. Canagliflozin-loaded magnetic nanoparticles as potential treatment of hypoxic tumors in combination with radiotherapy. *Nanomedicine (Lond).* **2018 Oct;13(19):2435-2454.** doi: 10.2217/nnm-2018-0145. Epub 2018 Oct 12. PMID: 30311542
34. Vlahopoulos S, Adamaki M, Khoury N, Zoumpourlis V, Boldogh I. Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer. *Pharmacol Ther.* **2019 Feb;194:59-72.** doi: 10.1016/j.pharmthera.2018.09.004. Epub 2018 Sep 19. PMID: 30240635
35. Khoury N, Zingkou E, Pampalakis G, Sofopoulos M, Zoumpourlis V, Sotiropoulou G. KLK6 protease accelerates skin tumor formation and progression. *Carcinogenesis.* **2018 Dec 31;39(12):1529-1536.** doi: 10.1093/carcin/bgy110. PMID: 30137206
36. Baliou S, Adamaki M, Kyriakopoulos AM, Spandidos DA, Panayiotidis M, Christodoulou I, Zoumpourlis V. CRISPR therapeutic tools for complex genetic disorders and cancer (Review). *Int J Oncol.* **2018 Aug;53(2):443-468.** doi: 10.3892/ijo.2018.4434. Epub 2018 Jun 6. PMID: 29901119.
37. Mitsiogianni M, Amery T, Franco R, Zoumpourlis V, Pappa A, Panayiotidis MI. From chemo-prevention to epigenetic regulation: The role of isothiocyanates in skin cancer prevention. *Pharmacol Ther.* **2018 Oct;190:187-201.** doi: 10.1016/j.pharmthera.2018.06.001. Epub 2018 Jun 8. PMID: 29890115
38. Cheimonidi C, Samara P, Polychronopoulos P, Tsakiri EN, Nikou T, Myrianthopoulos V, Sakellaropoulos T, Zoumpourlis V, Mikros E, Papassideri I, Argyropoulou A, Halabalaki M, Alexopoulos LG, Skaltsounis AL, Tsitsilonis OE, Aligiannis NN, Trougakos IP. Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights. *Redox Biol.* **2018 Jun;16:169-178.** doi: 10.1016/j.redox.2018.02.015. Epub 2018 Mar 1. PMID: 29505920
39. Devetzi M, Goulielmaki M, Khoury N, Spandidos DA, Sotiropoulou G, Christodoulou I, Zoumpourlis V. Genetically-modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)-based targeted therapy (Review). *Int J Mol Med.* **2018 Mar;41(3):1177-1186.** doi: 10.3892/ijmm.2018.3361. Epub 2018 Jan 3. PMID: 29328364
40. Baliou S, Adamaki M, Kyriakopoulos AM, Spandidos DA, Panayiotidis M, Christodoulou I, Zoumpourlis V. Role of the CRISPR system in controlling gene transcription and monitoring cell fate (Review). *Mol Med Rep.* **2018 Jan;17(1):1421-1427.** doi: 10.3892/mmr.2017.8099. Epub 2017 Nov 16. PMID: 29257248
41. Panagiotaki KN, Sideratou Z, Vlahopoulos SA, Paravatou-Petsotas M, Zachariadis M, Khoury N, Zoumpourlis V, Tsiourvas D. A Triphenylphosphonium-Functionalized Mitochondriotropic Nanocarrier for Efficient Co-Delivery of Doxorubicin and Chloroquine and Enhanced Antineoplastic Activity. *Pharmaceuticals (Basel).* **2017 Nov 21;10(4):91.** doi: 10.3390/ph10040091 PMID: 29160846
42. Kyriakopoulos AM, Nagl M, Baliou S, Zoumpourlis V. Alleviating Promotion of Inflammation and Cancer Induced by Nonsteroidal Anti-Inflammatory Drugs. *Int J*

- Inflam. 2017;2017:9632018.** doi: 10.1155/2017/9632018. Epub 2017 May 10. PMID: 28573063
43. Anthony M Kyriakopoulos, Stella Balliou, Nikolas Khoury and Vasillios Zoumpourlis. Towards Making the Real Antidote for Malaria. *EC Microbiology* 2017 March 17: 191-194
 44. Zoumpourlis V, Skourti E, Goulielmaki M, Vlahopoulos S, Christodoulou I. The Ideological Frame of the Genetic Basis of Cancer: The Important Role of miRNAs. ***Crit Rev Oncog. 2017;22(3-4):303-311.*** doi: 10.1615/CritRevOncog.2017024535 PMID: 29604906
 45. Adamaki M, Goulielmaki M, Christodoulou I, Vlahopoulos S, Zoumpourlis V. Homeobox Gene Involvement in Normal Hematopoiesis and in the Pathogenesis of Childhood **Leukemias.** ***Crit Rev Oncog. 2017;22(3-4):157-185.*** doi: 10.1615/CritRevOncog.2017024465. PMID: 29604897
 46. Galtsidis S, Logotheti S, Pavlopoulou A, Zampetidis CP, Papachristopoulou G, Scorilas A, Vojtesek B, Gorgoulis V, Zoumpourlis V. Unravelling a p73-regulated network: The role of a novel p73-dependent target, MIR3158, in cancer cell migration and invasiveness. ***Cancer Lett. 2017 Mar 1;388:96-106.*** doi: 10.1016/j.canlet.2016.11.036. Epub 2016 Dec 3. PMID: 27919789
 47. Voulgari E, Bakandritsos A, Galtsidis S, Zoumpourlis V, Burke BP, Clemente GS, Cawthorne C, Archibald SJ, Tuček J, Zbořil R, Kantarelou V, Karydas AG, Avgoustakis K. Synthesis, characterization and in vivo evaluation of a magnetic cisplatin delivery nanosystem based on PMAA-graft-PEG copolymers. ***J Control Release. 2016 Dec 10;243:342-356.*** doi: 10.1016/j.jconrel.2016.10.021. Epub 2016 Oct 26. PMID: 27793687
 48. Rizos E, Sifakas N, Skourti E, Papageorgiou C, Tsoporis J, Parker TH, Christodoulou DI, Spandidos DA, Katsantoni E, Zoumpourlis V. miRNAs and their role in the correlation between schizophrenia and cancer (Review). ***Mol Med Rep. 2016 Dec;14(6):4942-4946.*** doi: 10.3892/mmr.2016.5853. Epub 2016 Oct 14. PMID: 27748
 49. Nekulova M, Holcakova J, Gu X, Hrabal V, Galtsidis S, Orzol P, Liu Y, Logotheti S, Zoumpourlis V, Nylander K, Coates PJ, Vojtesek B. Δ Np63 α expression induces loss of cell adhesion in triple-negative breast cancer cells. ***BMC Cancer. 2016 Oct 10;16(1):782.*** doi: 10.1186/s12885-016-2808-x. PMID: 27724925
 50. Dinda B, Kyriakopoulos AM, Dinda S, Zoumpourlis V, Thomaidis NS, Velegriaki A, Markopoulos C, Dinda M. Cornus mas L. (cornelian cherry), an important European and Asian traditional food and medicine: Ethnomedicine, phytochemistry and pharmacology for its commercial utilization in drug industry. ***J Ethnopharmacol. 2016 Dec 4;193:670-690.*** doi: 10.1016/j.jep.2016.09.042. Epub 2016 Oct 2 PMID: 27705748 Review
 51. Georgadaki K, Khoury N, Spandidos DA, Zoumpourlis V. The molecular basis of fertilization (Review). ***Int J Mol Med. 2016 Oct;38(4):979-86.*** doi: 10.3892/ijmm.2016.2723. Epub 2016 Aug 31. PMID: 27599669
 52. Logotheti S, Khoury N, Vlahopoulos SA, Skourti E, Papaevangelidou D, Liloglou T, Gorgoulis V, Budunova I, Kyriakopoulos AM, Zoumpourlis V. N-bromotaurine surrogates for loss of antiproliferative response and enhances cisplatin efficacy in cancer cells with impaired glucocorticoid receptor. ***Transl Res. 2016 Jul;173:58-73.e2.*** doi: 10.1016/j.trsl.2016.03.009. Epub 2016 Mar 21 PMID: 27063960
 53. Skourti E, Logotheti S, Kontos Ch, Pavlopoulou A, Dimoragka P, Trougakos I, Gorgoulis V, Scorilas A, Ioannis Michalopoulos I and Zoumpourlis V. Altered expression of miR-200 family members, miR-205 and their co-regulated mRNA targets during mouse skin carcinogenesis. ***Mol Carcinog. 2016 Aug;55(8):1229-42.*** doi: 10.1002/mc.22365. Epub 2015 Aug 2 PMID: 26527515

54. Georgia Saxami , Athanasios Karapetsas , Eleftheria Lampranidou b, Ioan nis Kotsianidis , Aikaterini Chlichlia , Chrysoula Tassou c, Vassilis Zoumpourlis , Alex Galanis. Two potential probiotic lactobacillus strains isolated from olivemicrobiota exhibit adhesion and anti-proliferative effects in cancer cell lines. ***Journal of Functional Foods* 24 (2016)** 461–471
55. Rizos E, Siafakas N, Katsantoni E, Skourti E, Salpeas V, Rizos I, Tsoporis JN, Kastania A, Filippopoulou A, Xiros N, Margaritis D, Parker TG, Papageorgiou C, Zoumpourlis V. Correction: Let-7, Mir-98 and Mir-181 as Biomarkers for Cancer and Schizophrenia. ***PLoS One*. 2015 Aug 12;10(8):e0135863.** doi: 10.1371/journal.pone.0135863. eCollection 2015 PMID: 26266816
56. Rizos E, Siafakas N, Katsantoni E, Skourti E, Salpeas V, Rizos I, Tsoporis J, Kastania A, Filippopoulou A, Xiros N, Margaritis D, Parker T, Papageorgiou Ch, Vassilios Zoumpourlis. Let-7, Mir-98 and Mir-181 as Biomarkers for Cancer and Schizophrenia. ***PLoS One*. 2015 Apr 9;10(4):e0123522.** doi: 10.1371/journal.pone.0123522. eCollection 2015. PMID: 25856466
57. Rudrapaul P, Kyriakopoulos A, Chandra De U, Zoumpourlis V and Dinda B. New flavonoids from the fruits of *Cornus mas*, Cornaceae. ***Phytochemistry letters* 11, 292-295, 2015**
58. Georgios Pampalakis, Osahon Obasuyi, Olga Papadodima, Aristotelis Chatziioannou, Vassileios Zoumpourlis, Georgia Sotiropoulou. Kallikrein-related peptidase 5 is a novel suppressor of breast cancer that may exert its effects by repressing the mevalonate pathway. ***Oncotarget*. 2014 May 15;5(9):2390-403.** doi: 10.18632/oncotarget.1235. PMID: 24158494
59. Georgia Velimezi, Michalis Lontos, Konstantinos Vougas, Theodoros Roumeliotis, Maria Sideridou, Ayguel Dereli-Oz, Maciej Kocylowski, Ioannis S Pateras, Kostas Evangelou, Athanassios Kotsinas, Ines Orsolich, Sladana Bursac, Maja Cokaric-Brdovak, Vassilis Zoumpourlis, Dimitris Kletsas, George Papafotiou, Apostolos Klinakis, Sinisa Volarevic, Wei Gu, Jiri Bartek, Thanos D. Halazonetis, Vassilis Gorgoulis. Functional interplay between the DNA damage response kinase ATM and ARF tumour suppressor protein in human cancer. ***Nat Cell Biol*. 2013 Aug;15(8):967-77.** doi: 10.1038/ncb2795. Epub 2013 Jul 14
60. Logotheti S, Pavlopoulou A, Galtsidis S, Vojtesek B. and Zoumpourlis V. Functional discrimination of TAp73 isoforms in oncogenesis based on differences in their C-terminal domain. ***Cancer Metastasis Rev* (2013) 32:511–534,** DOI 10.1007/s10555-013-9424-x. PMID: 23592418
61. Christodoulou I, Kolisis FN, Papaevangelidou D and V Zoumpourlis. Proliferation kinetics and phenotypic properties of hMSCs derived from fetal umbilical cord (Wharton's jelly) and adult adipose tissue during prolonged in vitro culture. ***Stem Cells Int*. 2013;2013:246134.** doi: 10.1155/2013/246134. Epub 2013 Mar 3. PMID: 23533440
62. Georgakopoulou E.A., Tsimaratou K1, Evangelou K1., Pablo Jose Fernandez Marcos, Zoumpourlis V, Trougakos IP., Kletsas D, Bartek J., Serrano M., Gorgoulis VG. Specific lipofuscin staining by Sudan Black B as a novel approach to detect senescent cells in vitro, as well as in cryo-preserved and archival tissues. ***Aging (Albany NY)*. 2013 Jan;5(1):37-50.** doi: 10.18632/aging.100527. PMID: 23449538
63. Hio Chung Kang, Yuichi Wakabayashi, Kuang-Yu Jen, Jian-Hua Mao, Vassilis Zoumpourlis, Reyno De Rosario, and Allan Balmain. Ptch1 overexpression drives skin carcinogenesis and developmental defects in K14PtchFVB mice. ***J Invest Dermatol*. 2013 May;133(5):1311-20.** doi: 10.1038/jid.2012.419. Epub 2012 Dec 6. PMID: 23223138
64. Rizos E, Siafakas N, Koumarianou A, Katsantoni E, Filippopoulou A, Ntounas P, Touloumis Ch, Kastania A, Zoumpourlis V. miR-183 as a molecular and protective biomarker for cancer in schizophrenic subjects. ***Oncol Rep*. 2012 Dec;28(6):2200-4.** doi: 10.3892/or.2012.2052. Epub 2012 Sep 21 PMID: 23007659

65. Stella Igotheti, Dimitra Papaevangelou, Ioannis Christodoulou, Katerina Pyrillou, John Michalopoulos, Vassilis G. Gorgoulis, Spiros Vlachopoulos and Vassilis Zoumpourlis. Involvement of Estrogen Receptor alpha (ER α) in Mouse Skin Carcinogenesis ***PLoS One***;7(8):e41957. Epub 2012 Aug 3, 2012. PMID: 22870269
66. Ioannis Aivaliotis, Antonia Daleziou, Ioannis Pateras, Vassilis Zoumpourlis. "How do cytokines trigger genomic instability?" ***J Biomed Biotechnol***. :536761. Epub 2012 Jun 17, 2012 PMID: 22754280
67. Volanis D, Zaravinos A, Kadiyska T, Delakas D, Zoumpourlis V, Spandidos DA. Expression profile of Rho kinases in urinary bladder cancer. ***J. BUON*** 16(3):511-21, 2011 PMID: 22006759
68. Alexandros Daskalos, Sultana Markopoulou, George Xenarianos, John R Cosney, Stella Igotheti, Vassilis Zoumpourlis. John K. Field, and Triantafyllos Liloglou. Global DNA hypomethylation-induced DNP73 transcriptional activation in non-small cell lung cancer. ***Cancer Letters*** 300:79-86, 2011. PMID: 20926182
69. Igotheti S, Michalopoulos I, Sideridou M, Daskalos A, Kossida S, Spandidos DA, Field JK, Vojtesek B, Liloglou T, Gorgoulis V, Zoumpourlis V. Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73gamma in lung cancer. ***FEBS J***. 2010 Jul;277(14):3014-27. doi: 10.1111/j.1742-4658.2010.07710.x. Epub 2010 Jun 7. PMID: 20528922
70. Rizos EN, Michalopoulou PG, Siafakas N, Stefanis N, Douzenis A, Rontos I, Laskos E, Kastania A, Zoumpourlis V, Lykouras L. Association of Serum Brain-Derived Neurotrophic Factor and Duration of Untreated Psychosis in First-Episode Patients with Schizophrenia. ***Neuropsychobiology***. 2010;62(2):87-90. doi: 10.1159/000315438. Epub 2010 Jun 3. PMID: 20523079
71. Volanis D, Kadiyska T, Galanis A, Delakas D, Igotheti S, Zoumpourlis V. Environmental factors and genetic susceptibility promote urinary bladder cancer. ***Toxicol Lett***. 2010 Mar 15;193(2):131-7. doi: 10.1016/j.toxlet.2009.12.018. Epub 2010 Jan 4. PMID: 20051252
72. Michalis Lontos, Katerina Niforou, Georgia Velimezi Konstantinos Vougas, Konstantinos Evangelou, Radek Vrtel, Alexandros Damalas, Panayiotis Kontovazenitis, Athanassios Kotsinas, Vassilis Zoumpourlis, George Th. Tsangaris, Christos Kittas, Doron Ginsberg, Thanos D. Halazonetis, Jiri Bartek and Vassilis G. Gorgoulis . Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas. ***Am J Pathol***. 2009 Jul;175(1):376-91. doi: 10.2353/ajpath.2009.081160. Epub 2009 Jun 18. PMID: 19541929
73. Georgios Pampalakis, Evangelia Prosnikli, Theodora Agalioti, Antonia Vlahou, Vassilis Zoumpourlis and Georgia Sotiropoulou. A tumor protective role for human kallikrein 6 in breast cancer. ***Cancer Res***. 2009 May 1;69(9):3779-87. doi: 10.1158/0008-5472.CAN-08-1976. Epub 2009 Apr 21. PMID: 19383923
74. Copland J, Sheffield-Moore M, Koldzic Zivanovic C, Lamprou G, Tzortzatu-Stathopoulou F, Zoumpourlis V, Urban R, and Vlahopoulos S Sex steroids and their receptors at the crossroads between differentiation and neoplasia: a perspective for therapeutic intervention. ***Bioessays***. 2009 Jun;31(6):629-41. doi: 10.1002/bies.200800138. PMID: 19382224
75. Woodcock S, Rooney C, Lontos M, Connolly Y, Zoumpourlis V, Whetton A, Gorgoulis V and A Malliri. Src-induced disassembly of adherens junctions requires localised phosphorylation and degradation of Tiam-1. ***Mol Cell***. 2009 Mar 13;33(5):639-53. doi: 10.1016/j.molcel.2009.02.012. PMID: 19285946
76. Rizos EN, Siafakas N, Stefanis N, Douzenis A, Kontaxakis V, Laskos E, Kastania A, Zoumpourlis V, Lykouras L Association of serum BDNF and val66met polymorphism of the brain-derived neurotrophic factor in a sample of first psychotic episode patients. ***Psychiatriki***. 2009 Oct;20(4):297-304. PMID: 22218230

77. Frydrych I, Mlejnek P, Dolezel P, Zoumpourlis V, Krumpochova P. The broad-spectrum caspase inhibitor Boc-Asp-CMK induces cell death in human leukaemia cells. **Toxicol In Vitro.** **2008 Aug;22(5):1356-60.** doi: 10.1016/j.tiv.2008.02.017. Epub 2008 Mar 4.PMID: 18434077
78. Spiros A. Vlahopoulos, Stella Logotheti, Dimitris Mikas, Athina Giarika, Vassilis Gorgoulis and Vassilis Zoumpourlis. The role of ATF-2 in oncogenesis. **Bioessays.** **2008 Apr;30(4):314-27.** doi: 10.1002/bies.20734.PMID: 18348191.
79. Bakas P, Liapis A, Vlahopoulos S, Giner M, Logotheti S, Creatsas G, Meligova AK, Alexis MN, Zoumpourlis V. Estrogen receptor alpha and beta in uterine fibroids: a basis for altered estrogen responsiveness. **Fertil Steril.** **2008 Nov;90(5):1878-85.** doi: 10.1016/j.fertnstert.2007.09.019. Epub 2007 Dec 31.PMID: 18166184
80. Lontos M, Koutsami M, Sideridou M, Evangelou K, Kletsas D, Levy B, Kotsinas A, Nahum O, Zoumpourlis V, Kouloukoussa M, Lygerou Z, Taraviras S, Kittas C, Bartkova J, Papavassiliou AG, Bartek J, Halazonetis TD, Gorgoulis VG. Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. **Cancer Res.** **2007 Nov 15;67(22):10899-909.** doi: 10.1158/0008-5472.CAN-07-2837.PMID: 18006835
81. Bartkova J, Rezaei N, Lontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Orntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J, Gorgoulis VG. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. **Nature.** **2006 Nov 30;444(7119):633-7.** doi: 10.1038/nature05268.PMID: 17136093
82. Vlahopoulos S, Zimmer WE, Jenster G, Belaguli NS, Balk SP, Brinkmann AO, Lanz RB, Zoumpourlis V and Schwartz RJ. Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene. **J Biol Chem.** **2005 Mar 4;280(9):7786-92.** doi: 10.1074/jbc.M413992200. Epub 2004 Dec 28.PMID: 15623502
83. Papoutsi Z, Kassi E, Papaevangelou D, Pratsinis H, Zoumpourlis V, Halabalaki M, Mitakou S, Kalofoutis A and P moutsatsou. Plant 2-Arylobenzofurans demonstrate a selective estrogen receptor modulator profile. **Steroids.** **2004 Oct-Nov;69(11-12):727-34.** doi: 10.1016/j.steroids.2004.07.005.PMID: 15579325
84. Papassava P, Gorgoulis V, Papaevangelou D, Vlahopoulos S, van Dam H, and Zoumpourlis V. Overexpression of Activated Transcription Factor 2 is required for tumor growth and progression in mouse skin tumors. **Cancer Res.** **2004 Dec 1;64(23):8573-84.** doi: 10.1158/0008-5472.CAN-03-0955.PMID: 15574764
85. Vlachopoulos S and V Zoumpourlis. "JNK": a key modulator of intracellular signaling. **Biochemistry (Mosc).** **2004 Aug;69(8):844-54.** doi: 10.1023/b:biry.0000040215.02460.45.PMID: 15377263 Review
86. Zoumpourlis V, Solakidi S., Papatoma A. and Papaevangelou D. Genetic alterations in signal transduction pathways implicated in tumour progression during multistage mouse skin carcinogenesis. **Carcinogenesis.** **2003 Jul;24(7):1159-65.** doi: 10.1093/carcin/bgg067. Epub 2003 May 9.PMID: 12807763
87. Gorgoulis V, Zacharatos P, Mariatos G, Kletsas D, Zoumpourlis V, Kittas Ch, Ryan K and Papavassiliou A.. p53 activates ICAM-1 (CD54) expression in an NF- κ B-independent manner. **EMBO J.** **2003 Apr 1;22(7):1567-78.** doi: 10.1093/emboj/cdg157.PMID: 12660163
88. Gazouli M, Kokotas S, Zoumpourlis V, Zacharatos P, Mariatos G, Kletsas D, Kittas Ch and Gorgoulis V. The complement inhibitor CD59 and the lymphocyte function-associated antigen-3 (LFA-3, CD58) genes possess functional binding sites for the p53 tumor suppressor protein. **Anticancer Res.** **2002 Nov-Dec;22(6C):4237-41.**PMID: 12553064

89. Katsanakis KD, Gorgoulis V, Papavassiliou A and Zoumpourlis V. The progression in the mouse skin carcinogenesis model is dependent on ERK1/2 signaling. ***Mol Med.* 2002 Oct;8(10):624-37.** PMID: 12477973
90. Psichari E, Balmain A, Plows D, Zoumpourlis V and Pintzas A. High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by Rho signaling. ***J Biol Chem.* 2002 Aug 16;277(33):29490-5.** doi: 10.1074/jbc.M112368200. Epub 2002 May 30. PMID: 12039949
91. Katsanakis K, Owen C, Zoumpourlis V. JNK and ERK signaling pathways in multistage mouse carcinogenesis: studies in the inhibition of signaling cascades as a means to understand their in vivo biological role. ***Anticancer Res.* 2002 Mar-Apr;22(2A):755-9.** PMID: 12014647
92. Plows D, Briassouli P, Owen C, Zoumpourlis V, Garrett M and A Pintzas. Ecdysone-inducible expression of oncogenic Ha-Ras in NIH 3T3 cells leads to transient nuclear localization of activated extracellular signal-regulated kinase regulated by mitogen-activated protein kinase phosphatase-1. ***Biochem J.* 2002 Mar 1;362(Pt 2):305-15.** doi: 10.1042/0264-6021:3620305. PMID: 11853538
93. Papatoma A, Zoumpourlis V, Balmain A and A Pintzas. Role of Matrix Metalloproteinase-9 in Progression of Mouse Skin Carcinogenesis. ***Mol Carcinog.* 2001 Jun;31(2):74-82.** doi: 10.1002/mc.1042. PMID: 11429784.
94. Kotsinas A, Gorgoulis VG, Zacharatos P, Mariatos G, Kokotas S, Liloglou T, Ikonomopoulos Zoumpourlis V, Kyroudi A, Field JK, Asimakopoulos PJ and Kittas Ch. Additional characterizaation of a hexanucleotide polymorphic site in the first intron of human H-ras gene: comparative study of its alterations in non-small cell lung carcinomas and sporadic invasive breast carcinomas. ***Cancer Genet Cytogenet.* 2001 Apr 15;126(2):147-54.** doi: 10.1016/s0165-4608(00)00407-6. PMID: 11376808
95. Gorgoulis VG, Zacharatos P, Mariatos G, Liloglou T, Kokotas S, Kastrinakis N, Kotsinas A, Athanasiou A, Foukas P, Vogiatzi T, Zoumpourlis V, Kletsas D, Ikonomopoulos J, Asimakopoulos PJ, Rossidakis G, Kittas Ch and Field JK. Deregulated expression of c-mos in non-small cell lung carcinomas: Relationship with p53 status, genomic instability and tumor kinetics. ***Cancer Res.* 2001 Jan 15;61(2):538-49.** PMID: 11212247
96. Gorgoulis VG, Zacharatos PV, Kotsinas A, Mariatos G, Liloglou T, Vogiatzi T, Foukas P, Rassidakis G, Garinis G, Ioannides T, Zoumpourlis V, Michail P O, Manolis EN, Field JK and Kittas Ch. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and genomic instability in Non-Small Cell Lung Carcinomes (NSCLCs). ***Molecular Medicine* 6, 208-237, 2000.** PMID: 10965496
97. Zoumpourlis Vassilis, Papassava Paraskevi, Linardopoulos Spyros, Gillespie David, Balmain Allan and Alexandros Pintzas. High levels of phosphorylated c-jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. ***Oncogene.* 2000 Aug 17;19(35):4011-21.** doi: 10.1038/sj.onc.1203732. PMID: 10962557
98. Gorgoulis V, Zacharatos P, Manolis E, Ikonomopoulos A, Damalas A, Rassidakis G, Zoumpourlis V, Kotsinas A, Rassidakis AN, Halazonetis T and Kittas C. Effects of p53 mutants derived from lung carcinomas bind the p53 - responsive element (p53 RE) of the MDM-2 gene. Relationship with MDM-2 expression. ***British Journal of Cancer* 77, 374-384, 1998** doi: 10.1038/bjc.1998.60. PMID: 9472631
99. Christeli E, Zoumpourlis V, Kiaris H, Ergazaki M, Vassilaros S and Spandidos DA. TGF- β 1 overexpression in breast cancer. Correlation with clinicopathological data. ***Oncol Rep.* 1996 Nov;3(6):1115-8.** doi: 10.3892/or.3.6.1115. PMID: 21594520
100. Gorgoulis V, Zoumpourlis V, Rassidakis GZ, Rassidakis AN, Spandidos DA and Kittas Ch. A molecular and immunohistochemical study of the MDM2 protein isoforms and

- p53 gene product in bronchogenic carcinoma. *J Pathol.* **1996 Oct;180(2):129-37.** doi: 10.1002/(SICI)1096-9896(199610)180:2<129::AID-PATH646>3.0.CO;2-8.PMID: 8976869
101. Zoumpourlis V and Spandidos DA. Transcriptional activation of the human immunodeficiency virus long terminal repeat sequences by retinoic acid in human epithelial and fibroblast tumor cell lines. *Int J Biol Markers.* **1996 Jul-Sep;11(3):153-8.** PMID: 8915710
 102. Zoumpourlis V, Zachos G, Halazonetis TD and Spandidos DA. Binding of wild-type and mutant forms of p53 protein in a specific DNA sequence of the first intron of the H-ras oncogene. *International Journal of Oncology* **7, 1035-1041, 1995.** doi: 10.3892/ijo.7.5.1035.PMID: 21552928
 103. Spandidos DA, Zoumpourlis V, Zachos G, Toas SH and Halazonetis TD. Specific recognition of a transcriptional element within the human H-ras proto-oncogene by the p53 tumor suppressor. *International Journal of Oncology* **7, 1029-1034, 1995.** doi: 10.3892/ijo.7.5.1029.PMID: 21552927
 104. Field JK, Kiaris H, Risk JM, Tsiriyotis C, Adamson R, Zoumpourlis V, Rowley H, Taylor K, Whittaker J, Howard P, Beirne JC, Gosney JR, Woolgar J, Vaughan ED, Spandidos DA and Jones AS. Head and neck cancer allelotype indicates as ordered allele loss consistent with a two hit model of carcinogenesis. *British Journal of Cancer* **72, 1180-1188, 1995.** doi: 10.1038/bjc.1995.483.PMID: 7577465
 105. Zachos G, Zoumpourlis V, Sekeris CE and Spandidos DA. Binding of the glucocorticoid and estrogen receptors to the human c-H-ras oncogene sequences. *Int J Oncol.* **1995 Mar;6(3):595-600.** doi: 10.3892/ijo.6.3.595.PMID: 21556576
 106. Gorgoulis V, Zoumpourlis V, Rassidakis G, Karameris A, Barbatis C, Spandidos DA and Kittas C. Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. P53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen (PCNA) labelling index. *Virchows Arch.* **1995;426(4):339-44.** doi: 10.1007/BF00191341.PMID: 7599785
 107. Spandidos DA, Zoumpourlis V, Gorgoulis V and Gourtsoyiannis NC. P53 expression in human small intestinal tumours. *Oncol Rep.* **1994 Sep;1(5):885-7.** doi: 10.3892/or.1.5.885.PMID: 21607460.
 108. Zoumpourlis V, Papadakis E, Delakas D, Cranidis A, Segas J, Papadakis H and Spandidos DA. Human lung, bladder and head and neck carcinoma tumors as compared to their normal tissue have elevated AP-1 activity and recognize sequence elements of the HIV-1 LTR. *Oncol Rep.* **1994 Mar;1(2):403-9.** doi: 10.3892/or.1.2.403.PMID: 21607374
 109. Zoumpourlis V, Ergazaki M and Spandidos DA. AP-1 recognizes sequence elements on HIV-1 LTR in human epithelial tumour cell lines. *Oncol Rep.* **1994 Mar;1(2):397-401.** doi: 10.3892/or.1.2.397.PMID: 21607373
 110. Field JK, Tsiriyotis C, Zoumpourlis V, Howard P and Jones AS. Allele loss on chromosome 3 in squamous cell carcinoma of the head and neck correlates with poor clinical prognostic indicators. *Int J Oncol.* **1994 Mar;4(3):543-9.** doi: 10.3892/ijo.4.3.543.PMID: 21566956
 111. Field JK, Zoumpourlis V, Spandidos DA and Jones AS. P53 expression and mutations in squamous cell carcinoma of the head and neck: Expression correlates with the patients use of tobacco and alcohol. *Cancer Detect Prev.* **1994;18(3):197-208.** PMID: 8076382
 112. Zoumpourlis V and Spandidos DA. Mitomycin C stimulates the expression of human immunodeficiency virus long terminal repeat sequences in rat and human fibroblasts. *Biochem Pharmacol.* **1993 Jul 6;46(1):178-81.** doi: 10.1016/0006-2952(93)90363-2.PMID: 8347129
 113. Spandidos DA, Eliopoulos A and Zoumpourlis V. Regulation of oncogene and AIDS virus expression by cis-platin compounds. *Journal of Chemotherapy* **5, 778-779, 1993**

114. Zoumpourlis V, Kerr DJ and Spandidos DA. Differential interaction of cis-platin with HIV-1 long terminal repeat in a resistant ovarian carcinoma cell line. ***Anticancer Drugs*. 1993 Feb;4(1):77-83.** doi: 10.1097/00001813-199302000-00010.PMID: 8457718
115. Zoumpourlis V, Eliopoulos A and Spandidos DA. Transcriptional activation of the human immunodeficiency virus long terminal repeat sequences by tumour necrosis factor. ***Anticancer Res*. 1992 Nov-Dec;12(6B):2065-8.**PMID: 1295450
116. Zoumpourlis V and Spandidos DA. Hexamethylene bisacetamide stimulates the expression of human immunodeficiency virus long terminal repeat sequences in rat and human fibroblasts. ***Anticancer Drugs*. 1992 Apr;3(2):163-7.** doi: 10.1097/00001813-199204000-00015.PMID: 1525395
117. Zoumpourlis V, Kerr DJ and Spandidos DA. Carboplatin as opposed to cis-platin does not stimulate the expression of the human immunodeficiency virus long terminal repeat sequences. ***Biochem Pharmacol*. 1992 Feb 4;43(3):650-4.** doi: 10.1016/0006-2952(92)90592-7.PMID: 1540220
118. Spandidos DA, Zoumpourlis V, and Lang JK. Cis-platin responsive sequences in the human c-myc promoter. ***Anticancer Res*. 1991 May-Jun;11(3):1339-42.**PMID: 1888169
119. Zoumpourlis V, Kerr DJ, Spandidos DA. Doxorubicin stimulates transcription from the human immunodeficiency virus long terminal repeat sequences. ***Cancer Lett*. 1991 Feb;56(2):181-5.** doi: 10.1016/0304-3835(91)90094-x PMID: 1705476
120. Zoumpourlis V, Patsilinacos P, Kotsinas A, Maurer HR, Lenas P, Spandidos DA Cisplatin stimulates the expression from the human immunodeficiency virus long terminal repeat sequences in human fibroblasts. ***Anticancer Drugs*. 1990 Oct;1(1):55-8.** doi: 10.1097/00001813-199010000-00010. PMID: 2131039
121. Spandidos DA, Zoumpourlis V, Kotsinas A, Tsiriyotis C and Sekeris CE. Response of human immunodeficiency virus long terminal repeat to growth factors and hormones. ***Anticancer Res*. 1990 Sep-Oct;10(5A):1241-5.**PMID: 2241099
122. Spandidos DA, Zoumpourlis V, Kotsinas A, Maurer HR and Pasilinacos P. Transcriptional activation of the human immunodeficiency virus long terminal repeat sequences by cis-platin. ***Genetic Analysis Techniques and Applications* 7, 138-141, 1990.** doi: 10.1016/0735-0651(90)90020-g.PMID: 1965411

Publications in refereed proceedings of international conferences and book chapters

1. Spandidos DA, Chatzipanagiotou M and **Zoumpourlis V**. Prognostic significance of oncogenes and onco-suppressor genes in lung cancer. In: Proceedings of Seminar on Lung Cancer. ***European School of Oncology*. Pp 26-29, 1994.**
2. Spandidos DA, Chatzipapangiotou M and **Zoumpourlis V**. Oncogene and onco-suppressor gene lesions in lung cancer. In : ***Proceedings of the International Congress for Lung Cancer*. G. Antypas (Ed.) Monduzzi Editore S.p.A. Bologna, Italy, pp 41-45, 1994.**
3. Pintzas A, **Zoumpourlis V** and D Plows. Regulation of components of AP-1 transcription factor by early and late Ras signals. "*Molecular mechanisms of signal transduction*", **JL Bos (Ed.), IOS Press, 57-61, 2000**

4. **Zoumpourlis V**, Papassava P, Pintzas A, Moutsatsou P and Katsanakis K. AP-1 transcription factors and steroid hormone receptors in multistage mouse skin carcinogenesis. *Epitheorse klinikes Farmakologias kai Farmakokinetikes*, **15**, 123-128, 2001.
5. **Zoumpourlis V**, Pintzas A, Papassava P, Solakidi S and Papaevangelliou. Biological and chemical approach of the inhibition of signaling cascade in mouse skin carcinogenesis. *Review of clinical Pharmacology and genetics, International Edition* **16 (1)**, pp111, 2002
6. E Psichari, A Balmain, D Plows, **V Zoumpourlis**, A Pintzas. MECHANISMS OF SIGNAL TRANSDUCTION-High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by RhoA signaling. *Journal of Biological Chemistry* **277 (33)**, 29490-29495, 2002
7. Vlahopoulos S and **V Zoumpourlis**. Structure of DNA and its relationship to cancer. *Chapter 1 pp 1-26, Genome and Proteome in Oncology, Nova Science, 2005*
8. Sotiropoulou G, Pampalakis G, Prosnikli E, **Zoumpourlis V**. Human kallikrein 6 suppresses the malignant phenotype of MDA-MB-231 human metastatic breast cancer cells. *AACR Meeting Abstracts, Volume 2006 (1)*, page 999, 2006
9. Volanis D, Zaravinos A, Kadiyska T, **Zoumpourlis V**, Delakas D, Spandidos DA. Expression analysis of the Rho kinases in urinary bladder cancer. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE*, **S55-S55**, 2010
10. Skourti E, Kontos, C, Scorilas A, and **Zoumpourlis V**. miR-200 family miRNAs and miR-3069 expression is significantly differentiated between early and late mouse skin carcinogenesis stages. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE*, **S79-S79**, 2013
11. E Rizos, N Siafakas, **V Zoumpourlis**. MicroRNAs as biomarkers for schizophrenia cancer and other CNS disorders-The role of mir-183 as a possible molecular protective biomarker for cancer in schizophrenic subjects. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE* **32**, **S79-S79**, 2013
12. S Galtsidis, S Logotheti, A Pavlopoulou, B Vojtesek, **V Zoumpourlis**. The miRNA-mediated effect of TAp73 isoforms on metastasis. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE* **34**, **S75-S75**, 2014.
13. E Rizos, N Siafakas, E Katsantoni, **V Zoumpourlis**. Schizophrenia and cancer: the key role of microRNAs as biomarkers in cancer, schizophrenia and other CNS disorders. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE* **34**, **S62-S62**, 2014.
14. I Christodoulou, A Kritikos, **V Zoumpourlis**. The anti-proliferative effects of naive and genetically-modified hMSCs on human cancer cells. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE* **34**, **S75-S75**, 2014.
15. E Skourti, S Logotheti, CK Kontos, A Scorilas, IP Trougkos and **V Zoumpourlis**. MiR-200 family miRNAs and miR-205 exhibit a functional role in the progression of the mouse skin carcinogenesis through downregulating specific oncogenes. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE* **34**, **S75-S75**, 2014.

16. **V Zoumpourlis**, E Skourti. The ideological frame of the determination of the genetic basis of cancer. **INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 34, S75-S75, 2014**
17. Stella Logotheti, Nikolas Khoury, Elena Skourti, Spiros A. Vlahopoulos, Vassilis Gorgoulis, Anthony M. Kyriakopoulos, **Vassilis Zoumpourlis**. Loss of antiproliferative response attributed to ablated glucocorticoid receptor function in mouse skin carcinogenesis is compensated by N-bromoamine taurine. **FEBS J 282 Supplement 1 July 2015.**
18. Cheimonidou C., Argyropoulou A., Samara P., Tsakiri E.N., Papassideri I., **Zoumpourlis V.**, Polychronopoulos P., Tsitsilonis O.E., Aligiannis N., Skaltsounis A.L., Trougakos I.P. SELECTIVE KILLING OF TUMOR CELLS BY THE NATURAL COMPOUND ACTEOSIDE. **66th Conference of the HSBMB, Athens, Greece, 2015.**
19. Sotiris Galtsidis, Stella Logotheti, Borek Vojtesek, **Vassilis Zoumpourlis**. miR-3158: a TAp73-induced target which inhibits epithelial-mesenchymal transition through downregulation of vimentin. **FEBS J 282 Supplement 1 July 2015.**
20. Christodoulou I, Kritikos A, Taki H, **Zoumpourlis V**. Naïve and genetically-modified hMSCs exhibit anti-proliferative effects on human cancer cells. **FEBS J 282 Supplement 1 July 2015.**
21. Evin Iscan, Umut Ekin, **VassilisZoumpourlis**, Khoury Nikos, Hani Alotaibi, Marta Nekulova, Borivoj Vojtesek, Stella Logotheti, Mehmet Oztürk. Mechanism of TAp73 beta-MDM2 Autoregulation. **FEBS J Supplement 1 October 2016.**
22. Umut Ekin, Evin Iscan, Stella Logotheti Khoury Nikos, Hani Alotaibi, Sana Ferroudj, Marta Nekulova, Borivoj Vojtesek, **Vassilis Zoumpourlis**, Mehmet Oztürk. TAp73-Beta Induces Tumor Inhibition in Hepatocellular Carcinoma. **FEBS J Supplement 1 October 2016.**
23. Nicola Khoury, Georgios Pampalakis, Eleni Zingkou, **Vassilis Zoumpourlis**, Georgia Sotiropoulou. KLK6 protease promotes tumor incidence and growth in skin. **The 46th Annual Meeting of the European Society for Dermatological Research, 7-10 September 2016, Munich, Germany**
24. Rizos, E.; Siafakas, N.; Papanastasiou, A.; Skourti, E.; Papageorgiou, C.; Tsoporis, J.; Parker, T.; Spandidos, D. A.; Katsantoni, E.; **Zoumpourlis, V**. Schizophrenia and Cancer: An Overview of the Co-Morbidity and the Role of MicroRNAs. **Int. J. Mol. Med. (2016), 38 (1), S17.**
25. Baliou, S.; Nagl, M.; Kyriakopoulos, A. M.; **Zoumpourlis, V**. The Anti-Cancer Effect of Bromo-Amine T (BAT). **Int. J. Mol. Med. (2017), 40 (1), S21.**
26. Rizos, E.; Siafakas, N.; Skourti, E.; Papageorgiou, C.; Tsoporis, J.; Parker, T.; Spandidos, D. A.; Katsantoni, E.; **Zoumpourlis, V**. Could Schizophrenia Be a Protective Factor against Cancer? The Possible Role of MicroRNAs on This Hypothesis. **Int. J. Mol. Med. (2017), 40 (1), S58.**
27. E Rizos, N Siafakas, E Skourti, C Papageorgiou, J Tsoporis, Th Parker, DA Spandidos, E Katsantoni, **V Zoumpourlis**. The low cancer risk in patients suffering from

schizophrenic spectrum disorder. The possible role of microRNAs. Future medication strategies. ***INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 42, S8-S8, 2018***

28. S Baliou, M Nagl, AM Kyriakopoulos, **V Zoumpourlis**. Taurine derivatives exhibit therapeutic effect against various cancers. ***INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 42, S9-S9, 2018***
29. Alkmini Negka, Panagiota Koralli, Maria Goulielmaki, Lida Evmorfia Vagiaki, Aristeia Pavlou, Giannis N Antoniou, Panagiotis E Keivanidis, Dimitris Moschovas, Apostolos Avgeropoulos, Aristotelis Xenakis, **Vassilis Zoumpourlis**, Antonia Dimitrakopoulou-Strauss, Vasilis Gregoriou, Christos L Chochos. Evidence for Natural Anticancer Properties of Conjugated Polymer Nanoparticles. ***Journal of Nuclear Medicine 61 (supplement 1), 1026-1026, 2020***
30. Kyriakos C Prousis, Ruben Canton-Vitoria, Georgia Pagona, Maria Goulielmaki, **Vassilis Zoumpourlis**, Nikos Tagmatarchis, Theodora Calogeropoulou. New cationic heptamethinecyanine-graphene hybrid materials. ***Dyes and Pigments 175, 108047, 2020***

Competitively funded Projects:

1. ***PENED (1999-2002) (National Hellenic Research Foundation)***. Research program on "Mechanism of interaction of selective steroid receptor modulators with AP-1", a competitive GSRT research network. Coordinator : V. Zoumpourlis (Budget **142 K€**)
2. ***ENTER-01EP94: (2003-2007): (National Hellenic Research Foundation , Participant: Antisel SA)***. "Role of MEF2 transcription factor in heart hypertrophy and cancer development". Coordinator: V. Zoumpourlis. (Budget **73.3 K€.**)
3. ***Czech-Greek bilateral cooperation (2003-2005): (National Hellenic Research Foundation, Masaryk Memorial Cancer Institute Brno Czech, Participant: Antisel SA)***. "Role of the p53 oncosuppressor gene in androgen-independent prostate cancer". Contributor: Prof B Vojtesek, Coordinator: V. Zoumpourlis (Budget **24 K€**)
4. ***French-Greek bilateral cooperation (2004–2006): (National Hellenic Research Foundation, Institute Pasteur, Paris France, Participant: Antisel SA)***. "Molecular mechanism for Androgen Receptor interaction with AP-1 in Prostate cancer". Contributor: Prof M Yaniv, Coordinator: V. Zoumpourlis (Budget **24 K€.**)
5. ***USA - Greek bilateral cooperation (2005- 2008): (National Hellenic Research Foundation)***. «Molecular dissection of the mechanism of Rho kinase in susceptibility to cancer progression and metastasis». Contributor: Prof A Balmain, Coordinator: V. Zoumpourlis (Budget **60 K€.**)
6. ***EU project: TOK (2007-):*** (National Hellenic Research Foundation). «Supramolecular chemistry and gene therapeutic potential of amine-amine-substituted cyclodextrin end- functionalized triazine dendrimers based on melamine" Contributor: V. Zoumpourlis, Coordinator: I Kostas (total Budget **332 K€**)

7. *Czech-Greek bilateral cooperation (2012-2014): (National Hellenic Research Foundation, Masaryk Memorial Cancer Institute Brno Czech). "The regulation of p73 gene and the role of TAp73 β isoform in lung cancer ". Contributor: Prof B Vojtesek , Coordinator: V. Zoumpourlis (Budget **15 K€**)*
8. *ESPA (2012-2014) Action: Support for New Business, Research & Technological Development (Bioellenica Biotechnology Company S.A, Thessaloniki, GR, National Hellenic Research Foundation). "The use of genetically modified adipose-derived MSC in cancer cytotherapy. Coordinator: Prof. G Koliakos, Contributor: V. Zoumpourlis (total budget 200 K€; for National Hellenic Research Foundation 50 K€). This is a translational research program using the genetic modification of mesenchymal stem cells for cancer cytotherapy, through a robust collaboration with NHRF's spin-off Stem Cell Bank TAK- EIE, as well as with Biohellenika Biotechnology Company S.A.*
9. Research in stem cells (2008-) (*National Hellenic Research Foundation, TAK EIE*). "Research of stem cells and their applications in cancer therapeutics". Coordinator: V. Zoumpourlis (total budget **200 K€**).
10. KRYPTIS (2013-2015). Targeted therapeutic approaches against degenerative diseases with emphasis on cancer and aging. (*National Hellenic Research Foundation, Institute of Biology, Medical Chemistry and Biotechnology*) Contributor: V. Zoumpourlis (total budget 1500 K€ for Biomedical Application Unit budget **50 K€**).
11. *Greek – Turkey bilateral cooperation (2013-2015): (National Hellenic Research Foundation, Bilkent University Department of Molecular Biology and Genetics). "Role of p73 and its miRNA targets in chemosensitivity of liver cancer ". Contributor: Prof Mehmet Öztürk, Coordinator: V. Zoumpourlis (total budget 130 K€ for Biomedical Application Unit Budget **30 K€**).*
12. Czech-Greek cooperation (2014-2016): (*National Hellenic Research Foundation, Masaryk Memorial Cancer Institute Brno Czech*). "Comparative studies of wtp53 versus mutant p53 in scid mice. ". Contributor: Prof B Vojtesek , Coordinator: V. Zoumpourlis (Budget **12 K€**)
13. IKY Fellowships of Excellence for Postgraduate Studies in Greece- Siemens Program. 2014-2016. Coordinator: Dr. V Zoumpourlis. Post-graduate research fellow: Dr. Stella Logotheti. Total budget: 40 K€. Lab budget: **40 K€**.
14. KRYPTIS B (2017-2020). Targeted therapeutic approaches against degenerative diseases with emphasis on cancer and aging. (*National Hellenic Research Foundation, Institute of Biology, Medical Chemistry and Biotechnology*) Contributor: V. Zoumpourlis (total budget 800 K€ for Biomedical Application Unit budget **22 K€**).
15. IKY Fellowships of Excellence for Postgraduate Studies in Greece- Siemens Program. 2016-2017. Coordinator: Dr. V Zoumpourlis. Post-graduate research fellow: Dr. Marina Devetzi. Total budget: 30 K€. Lab budget: **30 K€**.

16. ELIDEK Phd fellowship. 2017-2019. Coordinator: Dr. V Zoumpourlis. Phd fellow: Mrs Maria Goulielmaki. Total budget: **18 K€**.
17. IKY Fellowships of Excellence for PhD Studies in Greece- Siemens Program. 2018-2021. Coordinator: Dr. V Zoumpourlis. PhD research fellow: Stella Baliou. Total budget: 30 K€. Lab budget: **30 K€**.
18. (EATRIS-GR) (2018-2021) Infrastructure for preclinical and early-phase clinical development of drugs, therapeutics and biomedical devices. Contributor: V. Zoumpourlis (total budget 500 K€ for Biomedical Application Unit budget **30 K€**).
19. EPAnEK (2018-2021) IDENTIFICATION OF NEW PROGNOSTICS BIOMARKERS FOR PROSTATE CANCER. (National Hellenic Research Foundation, Institute Chemical Biology) Contributor: V. Zoumpourlis (total budget **624 K€** for Biomedical Application Unit budget **214 K€**).
20. EPAnEK (2020-2023) Determination of genomic and transcriptomic prognostic bio-signatures in head and neck cancer. (National Hellenic Research Foundation, Institute of Chemical Biology) Coordinator: V. Zoumpourlis (total budget **824 K€** for Biomedical Application Unit budget **248 K€**).